Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

Vamvakas, Eleftherios C.; Blajchman, Morris A.

doi:10.1182/blood.v97.5.1180

Cited by 386 publications

(299 citation statements)

References 104 publications

Supporting

Mentioning

275

Contrasting

Unclassified

Order By: Relevance

“…TRIM has been associated with bacterial infection, multi-organ injury and mortality. 12 Leukoreduction of these stored units have been consistently associated with low rates of non-hemolytic febrile transfusion reactions. [13][14][15] Hebert and colleagues evaluated the impact of leukoreduction across 23 Canadian hospitals subsequent to a universal prestorage leukoreduction program.…”

Section: Discussionmentioning

confidence: 99%

Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting

Likosky

Paone

Zhang

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting

Likosky

Paone

Zhang

et al. 2015

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…In our study, we found an independent and significant association between The exact mechanism leading to this detrimental effect is far from being elucidated. Allogenic leukocytes and inflammatory mediators released during blood storage are thought to play a key role in the transfusion-associated immunomodulation [9,10]. However, neither leukocyte depletion nor transfusion of autologous blood favorably affects long-term oncological results.…”

Section: Discussionmentioning

confidence: 99%

“…Allogenic white blood cells and inflammatory cytokines have been shown to increase suppressor T-cell activity and inhibit natural killer cell activity, depressed macrophage and monocyte phagocyte activity. Besides the impairment of immune surveillance of cancer cells, the growth factors released during blood storage may also be responsible for tumor recurrence [9][10][11]. However, most studies evaluating proposed mechanisms have been done in animal models, and these findings may not be applicable to the human immune system.…”

Section: Introductionmentioning

confidence: 99%

Impact of Blood Transfusions on Survival and Recurrence in Colorectal Cancer Surgery

et al. 2012

View full text Add to dashboard Cite

The aim of our study was to evaluate the prognostic significance of blood transfusion on recurrence and survival in patients undergoing curative resections for colorectal cancer. Retrospective analysis of prospectively collected data of patients after elective resections for colorectal cancer between January 2001 and December 2009 was undertaken. The main endpoint was overall survival, disease-free survival, and recurrence rate. These data were evaluated in relation to blood transfusion (group A, no blood transfusion; group B, one to two blood transfusions; group C, three and more blood transfusions). A total of 583 patients met the criteria for inclusion in the study. Of these, 132 (22.6 %) patients received blood transfusion in the perioperative period. There were 83 (14.2 %) patients who received one or two blood transfusions and 49 (8.4 %) patients who required three or more transfusions. Patients with three or more transfusions had a significantly worse 5-year overall survival, disease-free survival, and increased incidence of distant recurrences in comparison with the group without transfusion or the group with one or two transfusions. Multivariate analysis showed that the application of three or more blood transfusions is an independent risk factor for overall survival (P 00.001; HR 2.158; 95 % CI 1.370-3.398), disease-free survival (P<0.001; HR 2.514; 95 % CI 1.648-3.836), and the incidence of distant recurrence (P<0.001; HR 2.902; 95 % CI 1.616-5.212). Application of three or more blood transfusions in patients operated for colorectal carcinoma is an adverse prognostic factor. Indications for blood transfusion should be carefully considered not only with regard to the risk of early complications, but also because of the possibility of compromising long-term results.

show abstract

“…Administering RBC transfusions in patients with thoracic malignancies translated into a higher perioperative A negative influence on the combined endpoint of cancer recurrence, death resulting from cancer recurrence, and overall mortality was observed after RBC transfusions in patients with colorectal, head and neck, breast, gastric, and prostate cancer [27].…”

Section: Cancer Treatment Outcomementioning

confidence: 99%

Management of Anemia in Cancer Patients: Transfusions

Schrijvers

2011

The Oncologist

View full text Add to dashboard Cite

show abstract

Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?

Cited by 386 publications

References 104 publications

Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting

Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting

Impact of Blood Transfusions on Survival and Recurrence in Colorectal Cancer Surgery

Management of Anemia in Cancer Patients: Transfusions

Contact Info

Product

Resources

About